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Abstract
Background: Major depressive disorder (MDD) is often comorbid with other chronic mental and physical health
conditions. Although the literature widely acknowledges the association of many chronic conditions with the risk of
MDD, the relative importance of these conditions on MDD risk in the presence of other conditions is not well
investigated. In this study, we aimed to quantify the relative contribution of selected chronic conditions to identify
the conditions most influential to MDD risk in adults and identify differences by age.
Methods: This study used electronic health record (EHR) data on patients empanelled with primary care at Mayo
Clinic in June 2013. A validated EHR-based algorithm was applied to identify newly diagnosed MDD patients
between 2000 and 2013. Non-MDD controls were matched 1:1 to MDD cases on birth year (±2 years), sex, and
outpatient clinic visits in the same year of MDD case diagnosis. Twenty-four chronic conditions defined by Chronic
Conditions Data Warehouse were ascertained in both cases and controls using diagnosis codes within 5 years of
index dates (diagnosis dates for cases, and the first clinic visit dates for matched controls). For each age group
(45 years or younger, between 46 and 60, and over 60 years), conditional logistic regression models were used to
test the association between each condition and subsequent MDD risk, adjusting for educational attainment and
obesity. The relative influence of these conditions on the risk of MDD was quantified using gradient boosting
machine models.
Results: A total of 11,375 incident MDD cases were identified between 2000 and 2013. Most chronic conditions
(except for eye conditions) were associated with risk of MDD, with different association patterns observed
depending on age. Among 24 chronic conditions, the greatest relative contribution was observed for diabetes
mellitus for subjects aged ≤ 60 years and rheumatoid arthritis/osteoarthritis for those over 60 years.
Conclusions: Our results suggest that specific chronic conditions such as diabetes mellitus and rheumatoid
arthritis/osteoarthritis may have greater influence than others on the risk of MDD.
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Background
Major depressive disorder (MDD) is highly prevalent, both
in the US and worldwide. Among US adults, the estimated
12-month and lifetime prevalence rates are 8.3 and 19.2 %,
respectively, and MDD is twice as common in women as in
men [1, 2]. The World Health Organization (WHO) con-
siders MDD to be the third-highest cause of disease burden
world-wide, and the highest cause of disease burden in the
developed world [3]. MDD is associated with declines in
overall health that are equivalent to cardiovascular disease,
diabetes, and arthritis, and the presence of chronic disease
with MDD contributes to greater disease burden and cost
to society than that of each illness alone [4].
Comorbidity refers to the presence of at least one extra
chronic disease along with a chronic disease of interest, and
is known to be common at all ages, but especially among
the elderly. Several studies have reported high rates of
MDD co-occurrence with many chronic somatic condi-
tions including cardiovascular diseases, cancer, and dia-
betes [5–8]. MDD patients with comorbid chronic somatic
conditions tend to have worse depression outcomes than
patients without such comorbidities, including more persist-
ent depressive symptoms, higher relapse rates, longer time
to recovery [9–11], and greater utilization of medical re-
sources [12]. These observations may be due to negative re-
ciprocal interactions between MDD, depressive symptoms,
and chronic somatic illness. Pain and functional impairment
associated with chronic conditions may increase the risk of
MDD, but MDD may also exacerbate the pain and distress
associated with somatic illnesses (NICE guidelines [CG91]
Published date: October 2009), suggesting a bi-directional
relationship between MDD and chronic somatic illness.
The majority of studies examining the relationship be-
tween MDD and chronic conditions have focused on asses-
sing MDD prevalence for a given somatic condition, which
does not permit the examination of specific chronic condi-
tions as risk factors for MDD in the context of other co-
occurring physical illnesses. Consideration of the compara-
tive contributions of specific chronic somatic conditions to
MDD risk in the context of all co-occurring conditions is
important, given that patients with chronic illnesses tend
to have more than one such condition, particularly if they
are depressed [8].
The age of MDD onset is highly variable. Community
surveys have suggested that incidence peaks occur during
ones’ 20’s and 50’s [13], although incident MDD can first
present at virtually any point across lifespan [14]. More re-
cent data suggest that a substantial number of cases
present very early in life, i.e., during childhood or adoles-
cence [15]. In addition to MDD onset, age is also strongly
associated with the types of commonly occurring chronic
conditions [16]. On that basis, it is possible that patterns
of co-occurring conditions will vary in MDD patients de-
pending on the age of MDD onset.
In this study, we aimed to investigate the association of
selected commonly-occurring chronic conditions on the
risk of MDD onset depending on age, and to quantify the
relative importance of each chronic condition on MDD
risk in the presence of all remaining physical conditions,
rather than examining each condition separately. In doing
so, we utilized electronic health record (EHR) data for as-
certaining MDD disease status and co-occurring chronic
conditions, offering the advantage of studying a large
population of over 11,000 MDD cases and an equal num-
ber of patients without MDD. We hypothesized that the
somatic conditions with the greatest relative importance
for MDD differ according to age.
Methods
Study subjects
In this study, we considered all adult (aged ≥ 18 years) pa-
tients empanelled with primary care in June, 2013 at Mayo
Clinic, Rochester, MN. These patients mostly resided in
Olmsted County, MN and the eight neighboring southeast
MN counties. EHRs were used to construct the cohort
and to ascertain the variables for this study. The EHR data
comprises longitudinal records of structured data (e.g., diag-
noses, procedures, and laboratory measurements) and un-
structured text (e.g., clinical notes, and pathology reports).
Subjects with newly diagnosed MDD
Cases of MDD that were newly diagnosed between 2000
and 2013 were identified using a validated EHR-based al-
gorithm [17]. Validation of this algorithm was conducted
prior to the current study. Briefly, the EHR-based algo-
rithm used to identify newly diagnosed MDD cases was
validated using data from 6923 subjects from the Mayo
Genomic Consortium, a cohort of Mayo Clinic patients
with EHR-linked data [18]. The algorithm identified 836
patients (12 %) with MDD. Of these, 82.3 % were con-
firmed as being true cases of newly diagnosed MDD using
manual chart review as a gold standard. All patients that
did not meet the electronic algorithm definition of newly
diagnosed MDD were confirmed by record review as be-
ing non-cases.
For the current study, MDD cases were identified on the
basis of having met at least two of the following criteria: ≥
2 MDD-related International Classification of Diseases, 9th
revision – Clinical Modification (ICD-9-CM) diagnosis
codes (296.2x, 296.3x), ≥ 1 anti-depressant prescription, ≥ 1
mention of MDD diagnoses within inpatient or outpatient
clinical notes, and ≥1 9-item Patient Health Questionnaire
(PHQ-9) score of 15 or higher. The National Drug File –
Reference Terminology (NDF-RT) [19] was used to identify
prescriptions for antidepressants (C8870), including tricyc-
lic antidepressants (C8872), monamine oxidase inhibitor
antidepressants (C8874), or other antidepressants (C8876).
Patients with diagnoses of bipolar disorders (ICD-9-CM:
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296.1x, 296.4x – 296.9x), dementia/delirium (ICD-9-CM:
290.x), or psychotic disorders (ICD-9-CM: 295.x, 298.x)
were excluded. The index date was defined as the first day
each subject met the EHR-based algorithm definition of
MDD. To eliminate prevalent MDD cases, MDD cases
were restricted to those with no evidence of a MDD diag-
nosis prior to their index date in their EHR records.
Control subjects
Each MDD case identified by the EHR algorithm was
paired with one control subject with no evidence of MDD-
related records (listed above) in their EHR. Controls also
could not have had prior diagnoses of schizophrenia, re-
lated primary psychotic disorders, or manic depressive ill-
ness/bipolar disorders. The control subjects were matched
1:1 with MDD cases on birth year (± 2 years), sex, and hav-
ing at least one outpatient clinic visit during the same study
year. The index date for control subjects was defined as the
date of the first clinic visit within the index study year.
Chronic conditions
All ICD-9-CM diagnosis codes (outpatient or inpatient)
were searched electronically for all subjects, using the 5 years
preceding the index dates. Although the EHR data were
available since 1994, the year 2000 was chosen as the start-
ing point for MDD ascertainment in order to provide at
least a 5 year ascertainment period for identifying chronic
conditions. These ICD-9-CM codes were used to define 24
chronic condition categories defined by the Chronic Condi-
tions Data Warehouse (https://www.ccwdata.org/web/guest/
condition-categories), after removing dementia/Alzheimer’s
disease and depression. To reduce false-positive misclassifi-
cation of the chronic conditions, only persons who received
at least two diagnostic codes for a given condition separated
by > 30 days were considered to have that condition [8, 16].
Additional data
Both obesity and socioeconomic deprivation have been asso-
ciated with multimorbidity involving both physical and
mental health conditions [20–22]. Therefore, we included
them in the analysis when quantifying the impact of chronic
conditions on MDD. Obesity was defined using the follow-
ing ICD-9-CM codes: 278.0, 564.2, V45.3, V45.86, 649.1,
649.2, V85.3, V85.4, and V77.8. We were unable to ascertain
a direct measure of socioeconomic status. Instead, we used
level of educational attainment as a proxy for socioeconomic
status. The highest level of education was self-reported from
a questionnaire administered to patients on at least a yearly
basis and categorized as high school or less, some college, 4-
year college degree, and post-graduate studies.
Statistical analysis
Demographic characteristics of incident MDD cases and
matched controls were summarized using proportions.
The number of chronic conditions and frequency of
each chronic condition were also presented, separately
for MDD cases and controls. Proportions for prostate
cancer and benign prostatic hyperplasia were calculated
for men only, while proportions for endometrial cancer
were calculated for women only.
For each stratum defined by age at index date (≤
45 years, 46 – 60 years, and over 60 years), conditional lo-
gistic regression models were applied to assess the associ-
ation of each chronic condition with risk of subsequent
MDD diagnosis, adjusting for educational attainment and
obesity. Odds ratios (ORs) and corresponding 95 % confi-
dence intervals (CIs) were presented. Gradient boosting
machine (GBM) models (including sex interaction) were
applied to quantify the relative influence (RI) of each
chronic condition on the risk of incident MDD diagnosis
in presence of other conditions as well as educational at-
tainment and obesity. The GBM modeling approach is a
machine learning technique for building a multivariable
prediction model by incorporating all of the variables
without variable selection [23, 24]. RI is a measure of a
given variable’s importance, relative to that of other vari-
ables, in the model prediction process. The measure is
based on the number of times a variable is selected for
splitting in a decision tree, weighted by the improvement
of the model fitting as a result of the split and further
standardized so that the sum of RI from all variables adds
up to 100 % [23–25]. For this analysis, the higher the RI
value of a given chronic condition, the more important it
is for the risk of incident diagnosed MDD, relative to the
other conditions included in the model. Within each of
the three age groups, chronic conditions occurring in at
least 1 % of the patients were analyzed. To assess the im-
pact of multiple chronic conditions, the GBM models
were applied with and without including the total disease
burden (the number of total chronic conditions among 24
conditions). For all analyses, we used R free statistical soft-
ware (http://cran.r-project.org) and related packages in-
cluding the gbm package.
Results
Demographic and clinical characteristics of the subjects
Among all patients receiving primary care at Mayo Clinic
during the study period, a total of 11,375 patients met the
definition of MDD during the study period. The majority
of patients were Caucasian; the median age at MDD diag-
nosis was 43 years and 65 % were female (Table 1). Slightly
greater than 30 % of these patients had an education level
of high school degree or less. MDD cases and non-MDD
controls were well-matched on age and sex.
Over 40 % of the incident MDD cases and slightly
under one-third of controls had at least one chronic
condition during the 5 years preceding the index dates
(Table1). For both MDD cases and non-MDD controls,
Ryu et al. BMC Psychiatry  (2016) 16:114 Page 3 of 9
the frequency of having at least one chronic condition
increased with age. Within each age stratum, the fre-
quency was higher for MDD cases compared controls
(Table 1).
The most prevalent chronic conditions among MDD
cases and non-MDD controls, regardless of age and sex,
are shown in Fig. 1. Of the 24 chronic conditions con-
sidered, hyperlipidemia was the most common in both
cases and controls (10.4 % vs 8.5 %), followed by hyper-
tension (10.0 % vs 7.0 %) and rheumatoid arthritis/osteo-
arthritis (RA/OA, 8.0 % vs 5.4 %). The frequencies of
nearly all chronic conditions (except for eye conditions
such as glaucoma and cataracts) were higher for the
cases compared to controls.
Association of chronic conditions with the risk of incident
MDD
Adjusting for educational attainment and obesity, the as-
sociation of each chronic condition with the risk of inci-
dent MDD diagnosis, stratified by age groups, is shown
in Fig. 2(a) through (c). In the youngest age stratum (≤
45 years), eight out of 24 chronic conditions occurred in
at least 1 % of the study subjects. Compared to controls,
MDD cases had significantly higher rate of diabetes melli-
tus (DM, 1.8 % vs. 0.6 % OR 2.8, 95 % CI 1.9 – 4.1), RA/
OA (1.8 % vs. 1.0 %, OR = 1.7, 95 % CI 1.2 – 2.3),
hypertension (3.5 % vs. 2.2 %, OR 1.5, 95 % CI 1.2 – 1.8),
and asthma (4.1 % vs. 2.7 %, OR = 1.5, 95 % CI 1.2 – 1.9).
No statistically significant between-group differences in
the rates of hypothyroidism, chronic obstructive pulmon-
ary disease, or anemia were observed.
In the 46–60 years old age stratum, 14 of the 24 chronic
conditions occurred in at least 1 % of study subjects. Sub-
jects with MDD had significantly higher rates of ischemic
heart disease (4.3 % vs 2.0 %, OR 2.4, 95 % CI 1.7 – 3.5),
DM (6.3 % vs 2.2 %, OR 2.1, 95 % CI 1.6 – 2.8), asthma
(3.7 % vs 2.0 %, OR= 1.7, 95 % CI 1.2 – 2.4), and RA/OA
(10.9 % vs 7.6 %, OR= 1.5, 95 % CI 1.2 – 1.9) compared to
controls. There were no statistically significant differences in
rates of osteoporosis, glaucoma, cataracts, or breast cancer.
For the oldest age stratum (>60 years), 20 of the 24
chronic conditions occurred in at least 1 % of study sub-
jects. Stroke (4.1 % vs 2.2 %, OR 1.9, 95 % CI 1.4 – 2.7) and
heart failure (5.3 % vs 2.4 %, OR 2.2, 95 % CI 1.6 – 3.0)
were strongly associated with MDD. The strength of asso-
ciation between RA/OA and MDD among persons aged
over 60 years was similar to those of other age groups
(20.6 % vs 14.1 %, OR 1.5, 95 % CI 1.3 – 1.8).
Relative contribution of chronic conditions to MDD risk in
the presence of education and obesity
Importance of each chronic condition on the risk of in-
cident MDD diagnosis varied according to age stratum
(Fig. 3). The most influential factor for all age strata was
educational attainment (RI = 34 %, 34 %, and 17 % for sub-
jects aged ≤ 45, between 46 and 60, and over 60 years, re-
spectively). Among the 24 chronic conditions that were the
main focus of this study, DM showed the greatest contribu-
tion to MDD risk for those aged 60 years or younger (RI of
13 % and 10 % for subjects aged ≤ 45 years, and 46 –
60 years, respectively). In the oldest age group (aged
over 60 years), the greatest contribution to MDD risk
was observed for RA/OA (RI of 10 %). Compared to
its significant contribution in younger age group (≤
60 years), DM showed little influence in older sub-
jects (RI = 2.1 %).
When the total disease burden (total number of co-
morbid conditions) was also considered for quantifying
relative contribution of individual somatic conditions to
MDD risk, all chronic conditions showed minimal in-
fluence regardless of age (RI less than 10 %), while
the total disease burden showed the greatest contribu-
tion (RI = 50 %, 42 %, and 36 % for subjects aged ≤
45 years, between 46 and 60, and over 60 years, re-
spectively). Educational attainment still showed a rela-
tively large contribution in the presence of the total
disease burden for MDD risk (RI = 21 %, 28 %, and
17 % for subjects aged ≤ 45 years, between 46 and 60,
and over 60 years, respectively).






Age (years) at index date, N (%)
45 or younger 6215 (54.6 %) 6218 (54.7 %)
Between 46 and 60 2732 (24.0 %) 2737 (24.1 %)
Over 60 2528 (21.3 %) 2420 (21.3 %)
Sex, female N (%) 7424 (65.3 %) 7423 (65.3 %)
Race, white N (%) 10,011 (88.0 %) 10,706 (94.1 %)
Education at index date
High school or less 3496 (30.7 %) 3708 (32.6 %)
Some college 3341 (29.4 %) 3788 (33.3 %)
College degree (4-year) 1779 (15.6 %) 1653 (14.5 %)
Post-graduate 1821 (16.0 %) 1383 (12.2 %)
Unknown 938 (8.3 %) 843 (7.4 %)
Diagnosed obesity, N (%) 699 (6.2 %) 382 (3.4 %)
Number of chronic conditions,
one or more N (%)
Overall 4741 (41.2 %) 3632 (31.9 %)
45 or youngera 1541 (24.8 %) 957 (15.4 %)
Between 46 and 60a 1360 (49.8 %) 1031 (37.7 %)
Over 60a 1840 (75.8 %) 1644 (67.9 %)
aFrequencies were calculated using the number of subjects in each age group
as the denominator
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Discussion
Epidemiological studies have documented strong and
significant associations between prevalent MDD and sev-
eral somatic health conditions [20, 26–30]. Most of this
literature has consisted of cross-sectional studies, or of
longitudinal studies focused primarily on single chronic
condition pairings with MDD. The results of cross-
sectional studies are limited in that documented associa-
tions between MDD and chronic conditions could re-
flect any of a number of combinations including (1) the
incidence of chronic conditions in patients with MDD,
(2) the incidence of MDD in people with specific health
conditions, (3) the effect of MDD and specific conditions
on the prognosis and mortality associated with one an-
other [26]. Studies focused on MDD associations with
single chronic health conditions are also limited in that
the relative influence of the conditions of interest on the
risk of MDD are often not considered in the context of
other comorbid physical health conditions. Consistent
with the current literature, we observed that almost all
chronic conditions considered showed some level of as-
sociation with MDD risk when considered individually,
even after accounting for educational attainment. When
considering all chronic conditions simultaneously, we
found that the greatest relative influence for MDD risk
was observed for diabetes mellitus among subjects aged
60 years or younger and RA/OA for subjects over
60 years. We also observed that the total disease burden
(measured as the number of chronic conditions) was the
greatest contributor for MDD risk, followed by socioeco-
nomic status (using education attainment as a surro-
gate). However, this study focused on identifying
individual chronic conditions with the greatest influence
on MDD risk, as it is difficult to implement clinical rec-
ommendations based on general disease burden without
also targeting co-occurring chronic somatic conditions
individually.
Although no single chronic condition had a very large
effect on the risk of MDD diagnosis, our findings support
existing recommendations for MDD screening when ad-
equate resources for follow-up diagnosis and treatment
are available, and highlight the importance of collaborative
depression care, especially for patients who are diagnosed
with the physical health conditions that may have greater
relative importance in terms of MDD risk. This is particu-
larly important in light of evidence that most patients with
chronic medical conditions do not receive proper diagno-
sis and treatment of psychiatric comorbidities [30].
In our study, diabetes had the greatest relative contri-
bution to depression in non-elderly adults even after ac-
counting for obesity. Epidemiological studies have long
documented an association between depression and
higher rates of type 1 and type 2 diabetes mellitus in
adults. In an influential meta-analysis of 20 controlled
Fig. 1 Frequency of chronic conditions occurred prior to index dates, separately by cases and controls. Proportions for prostate cancer and
benign prostate hyperplasia were among men and endometrial cancer was among women
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epidemiological studies, the risk of depression was twice
as high among persons with prevalent diabetes relative to
nondiabetic controls [31]. The association between depres-
sion and diabetes may be particularly strong for persons
with type 2 diabetes mellitus, although several prior studies
failed to control for several variables associated with in-
creased risk of clinically significant depression [32]. Numer-
ous models have been proposed in an attempt to provide
Fig. 2 Association of each chronic condition with the risk of MDD, stratified by different age group and adjusted by education attainment and
obesity. Three different age groups were used: subjects aged 45 or younger (a), subjects aged between 46 and 60 (b), and subjects aged 61 or older (c)
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mechanistic explanations for the high rates of depression-
diabetes co-occurrence. These include negative lifestyle fac-
tors and higher rates of overweight and obesity among de-
pressed individuals that increase the risk of new-onset type
2 diabetes, poorer adherence to diabetes treatment among
depressed relative to non-depressed persons, and orexigenic
effects of some antidepressant medications [33–36]. Add-
itionally, a number of shared biological mechanisms have
been hypothesized, including chronic hypothalamic-pituitary
adrenal (HPA) axis dysfunction leading to abnormal
glucocorticoid signaling, chronic inflammation, disruption
of normal circadian rhythms, and abnormalities in neurotro-
phin and monamine signaling [37, 38]. The identification of
targets for primary prevention of both type 2 diabetes and
depressive disorders based on the ascertainment of shared
etiological mechanisms is a current research priority [39].
Among subjects aged over 60 years, a significant contri-
bution to the risk of depression was made by RA/OA. As is
the case with diabetes, epidemiological studies have docu-
mented high rates of depressive disorder comorbidity
Fig. 3 Relative influence (%) of chronic conditions on MDD risk, stratified by different age group. Three different age groups were used: subjects
aged 45 or younger (a), subjects aged between 46 and 60 (b), and subjects aged 61 or older (c)
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among patients with RA [40], even after controlling for the
overlap in symptomatology between the two conditions
[41]. Pain and disability from RA has been proposed as one
clinical factor that may increase the risk of comorbid de-
pression, which may in turn worsen clinical outcome re-
lated to RA [42]. More recent studies have focused on
shared biological factors between depression and RA—spe-
cifically, the systemic inflammation that is characteristic of
RA and other inflammatory disorders may also have a role
in the development of depression, even among persons
without RA [43].
Our study has several limitations. First, case ascertain-
ment for MDD and the chronic conditions under con-
sideration was conducted solely based on information
from EHRs. Although our validated EHR-based algo-
rithm used multiple data sources (billing codes, clinical
notes, and medication use) to identify MDD cases, nei-
ther the MDD cases nor the chronic conditions in this
study were subject to confirmatory medical record re-
view. We also acknowledge that the information re-
corded in the medical records may not be accurate or
complete enough for a confirmatory diagnosis of MDD.
Second, medical records prior to 1994 were not utilized
in this study, as they were not available through our
EHR system. Therefore, it is possible that a proportion
of depression episodes occurred prior to 1994 would
have been missed, which potentially impacts our study
findings. Third, high rates of missed depression diagnoses
in clinical practice have been well supported in literature.
Thus, a proportion of controls may have undiagnosed de-
pression, which may have reduced statistical power to dis-
tinguish comorbidity patterns between cases and controls.
Fourth, diagnostic practice may have changed during the
study period (between 2000 and 2013). This could poten-
tially have affected the rates of diagnosis of MDD and co-
occurring somatic conditions. Fifth, the severity of MDD
was not incorporated in the current study, an important
consideration given evidence that MDD severity may cor-
relate with the severity of specific somatic conditions or
the number of co-occurring somatic conditions [44–48].
Sixth, the majority of our study population was Caucasian;
thus, our results should be replicated in more diverse pop-
ulations. As a related point, the mean age of our cohort is
younger than some other studies of multimorbidity in pri-
mary care populations [49]. For most patients, MDD has a
relatively early age of onset, typically less than 40 years of
age [13, 15]. Therefore, persons in this age range seeking
evaluation and treatment for MDD may be expected to
present to their primary care physicians. This seems par-
ticularly likely if they have existing chronic medical condi-
tions that are already being managed by their primary care
physicians—a condition that would seem to apply to our
study population. And finally, although education level
has been used in prior research as a proxy for
socioeconomic status [50], we were unable to adjust our
results for more direct measures of socioeconomic status.
Conclusion
Our results suggest that specific chronic conditions
such as diabetes mellitus and rheumatoid arthritis/osteo-
arthritis may have greater influence than others on the
risk of MDD. Ethics approval and consent to participate.
This study utilizing secondary EHR data was reviewed
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